Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

At the heart of Verona Pharma’s recent success is Ohtuvayre (ensifentrine), a revolutionary treatment for chronic obstructive pulmonary disease (COPD). According to David Zaccardelli, the President ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.

Wells Fargo has set a $50 target on Verona Pharma, suggesting the potential of Ohtuvayre, a treatment for Chronic Obstructive Pulmonary Disease (COPD), could exceed market expectations.

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Questex's Fierce Healthcare, Fierce Biotech and Fierce Pharma today announce the finalists of the Fierce Healthcare Innovation Awards and the Fierce Life ...

(MENAFN- GlobeNewsWire - Nasdaq) Showcases Outstanding Innovation Driving Improvements and Transforming the Industries NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Questex's Fierce Healthcare ...